Stockscreener 앱 받기
18.77
1.37%
-0.26
시간 외 거래:
18.54
-0.23
-1.23%
전일 마감가:
$19.03
열려 있는:
$18.69
하루 거래량:
660.93K
Relative Volume:
0.80
시가총액:
$2.10B
수익:
$418.33M
순이익/손실:
$-252.07M
주가수익비율:
-7.8208
EPS:
-2.4
순현금흐름:
$-238.84M
1주 성능:
+10.54%
1개월 성능:
+2.07%
6개월 성능:
-45.29%
1년 성능:
-32.89%
1일 변동 폭
$18.40
$19.12
1주일 범위
$16.96
$20.00
52주 변동 폭
$15.96
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
명칭
Zai Lab Limited Adr
전화
862161632588
주소
899 HALEI ROAD, SHANGHAI
Compare ZLAB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
18.77 | 2.13B | 418.33M | -252.07M | -238.84M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-03-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-14 | 개시 | Morgan Stanley | Overweight |
| 2023-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-01-21 | 개시 | Macquarie | Outperform |
| 2021-10-12 | 개시 | Bernstein | Mkt Perform |
| 2020-04-28 | 개시 | Goldman | Buy |
| 2020-04-15 | 개시 | Guggenheim | Buy |
| 2019-07-12 | 개시 | BofA/Merrill | Buy |
| 2019-07-05 | 개시 | Macquarie | Outperform |
| 2019-01-29 | 개시 | Credit Suisse | Outperform |
| 2018-11-21 | 개시 | Jefferies | Buy |
| 2018-06-21 | 재개 | Leerink Partners | Outperform |
| 2018-02-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 개시 | JP Morgan | Neutral |
| 2017-10-16 | 개시 | Leerink Partners | Outperform |
모두보기
Zai Lab Limited Adr 주식(ZLAB)의 최신 뉴스
Zai Lab Limited's (NASDAQ:ZLAB) Shift From Loss To Profit - Yahoo Finance
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
JPMorgan Chase & Co. Has Lowered Expectations for Zai Lab (NASDAQ:ZLAB) Stock Price - MarketBeat
$207B Market Shift: The Race for Fast Track Approval in Oncology - Benzinga
$207B Market Shift: The Race for Fast Track Approval in Oncology - Sahm
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Benzinga
Zai Lab (NASDAQ:ZLAB) Reaches New 1-Year Low – Time to Sell? - Defense World
Is UBS’s Global-Innovation Framing Rewriting Zai Lab’s (ZLAB) Long-Term Biopharma Platform Narrative? - Sahm
UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform - Finviz
Zai Lab (NASDAQ:ZLAB) Sets New 12-Month LowHere's Why - MarketBeat
8 High Growth Chinese Stocks To Buy - Insider Monkey
Zai Lab Limited (ZLAB) Stock Analysis: Eyeing a 169% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Zai Lab (NASDAQ:ZLAB) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Short Interest in AiRWA Inc. (NASDAQ:YYAI) Rises By 24.6% - Defense World
Short Interest in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Drops By 19.8% - MarketBeat
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Update - Defense World
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After New AUGTYRO Approval And Pipeline Progress - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Animalcare Group (LON:ANCR) Stock Passes Below 200-Day Moving Average – Here’s What Happened - Defense World
Simply Good Foods (NASDAQ:SMPL) Stock Crosses Below 200-Day Moving Average – Time to Sell? - Defense World
How Investors May Respond To Zai Lab (ZLAB) Winning Expanded China Approval For AUGTYRO Cancer Therapy - Sahm
Zai Lab (NASDAQ:ZLAB) Shares Gap UpWhat's Next? - MarketBeat
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
UBS gives Zai Lab (ZLAB) a buy rating - MSN
Zai Lab (NASDAQ:ZLAB) Research Coverage Started at UBS Group - Defense World
UBS Gives Zai Lab (ZLAB) a Buy Rating - Insider Monkey
Zai Lab (ZLAB) Is Up 7.9% After First-In-China AUGTYRO Approval Across TRK TKI Settings - Sahm
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors - BioSpace
China clears new AUGTYRO use for adults with NTRK‑positive cancers - Stock Titan
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference - BioSpace
The Truth About Zai Lab Ltd (ADR): Is This Sleeper Stock About To Explode Or Nah? - AD HOC NEWS
Zai Lab (NASDAQ:ZLAB) Insider Rafael Amado Sells 10,787 Shares - Defense World
The Truth About Zai Lab Ltd (ADR): Is This Sleeper Stock About To Explode Or Fade? - AD HOC NEWS
Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts - TechStock²
EBITDA per share of Zai Lab Ltd. Sponsored ADR – MUN:1ZL - TradingView — Track All Markets
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025 - ts2.tech
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Sahm
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia - Business Wire
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CapEx per share of Zai Lab Ltd. Sponsored ADR – MUN:1ZL - TradingView — Track All Markets
How Investors May Respond To Zai Lab (ZLAB) Advancing ZL-1503 Into Global Phase 1/1b Atopic Dermatitis Trial - Sahm
Zai Lab (NASDAQ:ZLAB) Hits New 12-Month LowTime to Sell? - MarketBeat
How Investors Are Reacting To Zai Lab (ZLAB) Advancing ZL-1503 And Securing Key NRDL Renewals - Sahm
Zai Lab (NASDAQ:ZLAB) Hits New 1-Year LowShould You Sell? - MarketBeat
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis - Business Wire
Zai Lab Announces Updates to China’s National Reimbursement Drug List - Business Wire
Zai Lab Limited Adr (ZLAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):